Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14649428 | 0.83 | PDE10A (0.42) | EGLN2PDE10A | |
| SCHEMBL22337954 | 0.74 | EGLN2 (0.49) | EGLN2 | |
| SCHEMBL9720035 | 0.74 | EGLN2 (0.45) | EGLN2 | |
| SCHEMBL3547481 | 0.74 | EGLN2 (0.45) | EGLN2 | |
| SCHEMBL22337956 | 0.71 | EGLN2 (0.42) | EGLN2 | |
| SCHEMBL19510416 | 0.70 | EGLN2 (0.58) | EGLN2 | |
| SCHEMBL21672416 | 0.69 | EGLN2 (0.41) | EGLN2 | |
| SCHEMBL3126997 | 0.69 | EGLN2 (0.41) | EGLN2 | |
| SCHEMBL863434 | 0.68 | PDE10A (0.36) | PDE10A | |
| SCHEMBL23143440 | 0.68 | EGLN2 (0.64) | EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078106-A1 | Substituted Piperidino Compounds and Related Methods of Treatment | ALKERMES INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12441710-B2 | Substituted piperidino compounds and related methods of treatment | ALKERMES, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4263506-B1 | SUBSTITUTED PIPERIDINO COMPOUNDS AND RELATED METHODS OF TREATMENT | ALKERMES INC (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240101577-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-03-28 | — | — | US | disclosed |
| US-20240076283-A1 | Substituted Piperidino Compounds and Related Methods of Treatment | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-03-07 | — | — | US | disclosed |
| EP-4326721-A1 | SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS | Protego Biopharma, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20240051960-A1 | SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS | PROTEGO BIOPHARMA, INC. | 2024-02-15 | — | — | US | disclosed |
| EP-4263506-A1 | SUBSTITUTED PIPERIDINO COMPOUNDS AND RELATED METHODS OF TREATMENT | Alkermes, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3724189-B1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2021058595-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2021-04-01 | — | — | WO | disclosed |
| US-20200407372-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2020-12-31 | — | — | US | disclosed |
| US-20200407372-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2020-12-31 | — | — | US | disclosed |
| WO-2020163193-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| EP-1784188-B1 | FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7625888-B2 | Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1784188-A4 | FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2009-06-24 | — | — | EP | disclosed |
| US-20070208010-A1 | Fused Triazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME CORP. | 2007-09-06 | — | — | US | disclosed |
| EP-1784188-A2 | FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006023750-A2 | FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078106-A1 | Substituted Piperidino Compounds and Related Methods of Treatment | HCRTR1, HCRTR2, NPY1R | EGLN2 289/4885PDE10A 696/4885 |
| US-20070208010-A1 | Fused Triazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | EGLN2 995/4885PDE10A 2946/4885 |
| US-12441710-B2 | Substituted piperidino compounds and related methods of treatment | HCRTR1, HCRTR2, PNMT | EGLN2 92/4885PDE10A 1031/4885 |
| US-20240101577-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPRJ | EGLN2 2348/4885PDE10A 864/4885 |
| US-20240051960-A1 | SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS | IGLV6-57, TTR, MAP1LC3C | EGLN2 3003/4885PDE10A 3818/4885 |
| US-20240076283-A1 | Substituted Piperidino Compounds and Related Methods of Treatment | HCRTR1, HCRTR2, PNMT | EGLN2 92/4885PDE10A 1031/4885 |
| US-20200407372-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPRJ | EGLN2 2348/4885PDE10A 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.